|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
4
|
|
gptkbp:bfsParent
|
gptkb:Gilead_Sciences
gptkb:sofosbuvir
gptkb:velpatasvir
|
|
gptkbp:activities
|
inhibits N S5 A protein
inhibits N S5 B polymerase
|
|
gptkbp:approves
|
gptkb:2016
gptkb:FDA
|
|
gptkbp:availability
|
widely available
|
|
gptkbp:clinical_trial
|
gptkb:ASTRAL-1
gptkb:ASTRAL-2
gptkb:ASTRAL-3
gptkb:ASTRAL-4
gptkb:SOLAR-1
Phase 3
chronic hepatitis C
|
|
gptkbp:contraindication
|
severe hepatic impairment
|
|
gptkbp:dosage_form
|
gptkb:tablet
gptkb:battle
|
|
gptkbp:duration
|
12 weeks
|
|
gptkbp:education
|
important for adherence
|
|
gptkbp:events
|
recommended after treatment
|
|
gptkbp:formulation
|
fixed-dose combination
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Epclusa
|
|
gptkbp:ingredients
|
gptkb:sofosbuvir
gptkb:velpatasvir
|
|
gptkbp:interacts_with
|
gptkb:St._John's_Wort
gptkb:carbamazepine
gptkb:rifampin
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_available_in
|
tablet form
|
|
gptkbp:is_monitored_by
|
viral load testing recommended
|
|
gptkbp:is_used_for
|
treatment of hepatitis C
|
|
gptkbp:manager
|
oral
|
|
gptkbp:manufacturer
|
gptkb:Gilead_Sciences
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:Australia
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:population
|
adults
pediatric patients
|
|
gptkbp:price
|
varies by region
|
|
gptkbp:provides_information_on
|
recommended by WHO
recommended by AASLD
recommended by EASL
|
|
gptkbp:requires
|
gptkb:battle
|
|
gptkbp:safety_features
|
required during treatment
|
|
gptkbp:scholarships
|
gptkb:stock_market_index
|
|
gptkbp:side_effect
|
gptkb:fandom
fatigue
headache
nausea
rash
insomnia
elevated liver enzymes
pruritus
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:treatment
|
sustained virologic response
over 95% in some populations
|